Core Points - Chemomab Therapeutics has appointed David M. Weiner, MD, as Interim Chief Medical Officer and Jack Lawler as Chief Development Officer, both bringing extensive experience in biotechnology and pharmaceutical R&D [1][2][4] - Dr. Weiner previously served as Interim CMO at Chemomab and has over 25 years of experience in drug development, while Mr. Lawler has 25 years of clinical drug development experience and has been with Chemomab since 2022 [1][5][8] - The company is preparing for the potential initiation of a Phase 3 trial for its drug nebokitug, which has shown promising results in the Phase 2 SPRING trial for primary sclerosing cholangitis (PSC) [10] Company Overview - Chemomab is a clinical stage biotechnology company focused on developing therapeutics for fibro-inflammatory diseases, with its lead product nebokitug being a first-in-class monoclonal antibody targeting CCL24 [10] - Nebokitug has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC treatment, indicating its potential for expedited regulatory review [10] - The company has reported positive results from four clinical trials of nebokitug, demonstrating a favorable safety profile and the potential to treat multiple severe fibro-inflammatory diseases [10]
Chemomab Announces New Medical and Clinical Appointments